Drug intelligence / Profile preview

EVT075

Development stage: Unknown
Lead developer: Evotec

Overview

EVT075 is a first-in-class immunomodulatory biologic developed by Evotec for the treatment of COVID-19. Designed to amplify the host's immune response against SARS-CoV-2, the therapeutic aims to reduce viral load and prevent progression to severe disease. The program is supported by a grant from the German Federal Ministry of Education and Research (BMBF) and utilizes Evotec's PRROTECT (Pandemic Preparedness and Response) platform and Just - Evotec Biologics manufacturing capabilities.

Beyond the preview

Go deeper on EVT075.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVT075.

Explore the full profile